What's Happening

The U.S. Food and Drug Administration has approved Eli Lilly's Inluriyo (imlunestrant) in combination with Verzenio (abemaciclib) for adults with a specific form of advanced or metastatic breast cancer.

The treatment is intended for patients whose tumors are estrogen receptor-positive (ER-positive), HER2-negative and carry an ESR1 mutation, and whose disease has progressed after at least one line of endocrine therapy. The FDA also approved the Guardant360 CDx companion diagnostic to identify patients with the relevant ESR1 mutations. (U.S. Food and Drug Administration)

The approval expands Lilly's position in a major segment of the breast cancer market and adds a combination approach to a disease area where treatment resistance can emerge after hormone therapy.

Who the Treatment Is For

The approval covers adults with:

  • ER-positive breast cancer, meaning the tumor grows in response to estrogen
  • HER2-negative disease
  • ESR1-mutated advanced or metastatic cancer
  • Disease that has progressed following at least one line of endocrine therapy

The ESR1 mutation is particularly important because it can emerge as breast cancer develops resistance to endocrine treatment. The FDA requires an FDA-authorized test to identify the relevant mutation before treatment with the combination. (U.S. Food and Drug Administration)

Lilly estimates that about half of patients with ER-positive, HER2-negative metastatic breast cancer develop an ESR1 mutation during or after treatment with commonly used hormone-blocking therapies.

Inluriyo Was Already Approved as a Standalone Treatment

This is not the first U.S. approval for Inluriyo.

The FDA originally approved imlunestrant in September 2025 for adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer whose disease had progressed following at least one line of endocrine therapy. (U.S. Food and Drug Administration)

The September 18, 2026 decision expands its use by allowing it to be combined with abemaciclib, the active ingredient in Lilly's Verzenio.

That means Lilly now has the same drug positioned both as a standalone endocrine treatment and as part of a combination regimen for an appropriate population. (U.S. Food and Drug Administration)

How the Two Drugs Work

The two medicines target different parts of the cancer-growth process.

Inluriyo: Inluriyo is an estrogen receptor antagonist. It works by blocking and breaking down estrogen receptors that can help certain breast cancer cells grow. It is taken as a daily oral tablet.

Verzenio: Verzenio is a CDK4/6 inhibitor. It works by slowing the division and growth of cancer cells.

Because the drugs work through different mechanisms, the combination is intended to provide additional control over tumor growth compared with Inluriyo alone.

The Clinical Trial Behind the Approval

The FDA based the decision on the EMBER-3 trial, a randomized, open-label, multicenter study involving 874 adults with ER-positive, HER2-negative locally advanced or metastatic breast cancer.

Participants had previously received an aromatase inhibitor, either alone or together with a CDK4/6 inhibitor. They were randomized to receive:

  • Inluriyo alone
  • An investigator's choice of endocrine therapy, either fulvestrant or exemestane
  • Inluriyo plus Verzenio (U.S. Food and Drug Administration)

The ESR1 mutation was identified through a blood-based circulating tumor DNA test using the Guardant360 CDx assay. (U.S. Food and Drug Administration)

Combination Nearly Doubled Median Progression-Free Survival

The most important result came from the subgroup of patients whose tumors carried an ESR1 mutation.

Among the 159 patients included in the exploratory ESR1-mutated subgroup analysis for the combination, median progression-free survival was:

  • 11.1 months with Inluriyo plus Verzenio
  • compared with 5.5 months with Inluriyo alone. (U.S. Food and Drug Administration)

The FDA reported a progression-free survival hazard ratio of 0.53 for the combination in this subgroup, with a 95% confidence interval of 0.35 to 0.80. (U.S. Food and Drug Administration)

Progression-free survival measures how long patients live without their cancer getting worse.

The FDA noted that overall-survival data were still immature at the time of the interim analysis, with 35% of deaths reported among patients with ESR1-mutated tumors. (U.S. Food and Drug Administration)

Response Rates Also Improved

The combination also produced a higher objective response rate in the ESR1-mutated population.

The FDA reported:

  • 35% objective response rate with Inluriyo plus Verzenio
  • versus 15% with Inluriyo alone. (U.S. Food and Drug Administration)

That measures the proportion of patients whose tumors showed a defined reduction in size under the trial's criteria.

The results therefore showed differences not only in how long patients remained free from disease progression, but also in the proportion whose tumors responded to treatment.

The Benefit Is Tied to ESR1-Mutated Disease

An important part of the FDA's analysis is that the benefit is not being presented as a broad advantage for every patient with ER-positive, HER2-negative advanced breast cancer.

The agency said the benefit observed with imlunestrant monotherapy was associated with the ESR1-mutated population, while no progression-free-survival improvement was demonstrated for imlunestrant monotherapy compared with investigator's choice in the overall population or in patients without detected ESR1 mutations. (U.S. Food and Drug Administration)

That makes genetic testing a central part of identifying appropriate patients.

The approval therefore connects drug treatment with companion diagnostics, rather than treating all advanced ER-positive, HER2-negative breast cancer patients as one population.

Companion Diagnostic Gets FDA Approval Too

Alongside the drug combination, the FDA approved the Guardant360 CDx assay as a companion diagnostic.

The test is designed to identify patients whose breast cancers carry the relevant ESR1 mutations and therefore may be eligible for the Inluriyo-Verzenio combination. (U.S. Food and Drug Administration)

This is commercially important because the growth of targeted therapies is increasingly linked to diagnostic testing.

In this case, the drug and diagnostic are effectively part of the same treatment-selection process.

Safety Risks Remain Important

The combination comes with several significant safety considerations.

For Inluriyo, the prescribing information includes a warning for embryo-fetal toxicity. (U.S. Food and Drug Administration)

Verzenio carries warnings and precautions involving:

  • Diarrhea
  • Neutropenia, or low levels of certain white blood cells
  • Interstitial lung disease or pneumonitis
  • Liver toxicity
  • Venous thromboembolism, including blood clots
  • Embryo-fetal toxicity (U.S. Food and Drug Administration)

Lilly's announcement cited by Reuters also identified severe diarrhea, low white blood cell counts, lung inflammation, liver problems and blood clots among the risks associated with the combination.

These risks mean patient selection, monitoring and treatment management remain important parts of using the regimen.

Recommended Dosing

The FDA recommends:

  • Inluriyo: 400 mg orally once daily, taken on an empty stomach, at least two hours before food or one hour after food.
  • Verzenio: 150 mg orally twice daily, with or without food.

Treatment continues until the cancer progresses or side effects become unacceptable. (U.S. Food and Drug Administration)

Both medicines are oral therapies, meaning the treatment does not require an infusion at an oncology center.

Why ESR1 Mutations Matter in Breast Cancer

ESR1 mutations are one mechanism by which hormone-receptor-positive breast cancer can become resistant to endocrine treatment.

That makes the mutation an increasingly important biomarker in advanced breast cancer treatment.

As patients move through successive lines of therapy, the ability to identify specific resistance mutations can help physicians determine whether a patient remains a candidate for a particular endocrine-based approach or may need another strategy.

The Lilly approval therefore reflects a broader move toward more biomarker-driven treatment decisions in oncology. (U.S. Food and Drug Administration)

Lilly Is Expanding an Existing Breast Cancer Franchise

The approval is commercially significant for Lilly because Verzenio is already a major oncology product.

The company can now pair Verzenio with its newer endocrine therapy for an identified subset of patients with advanced breast cancer.

The strategy gives Lilly an opportunity to use an established drug alongside a newer medicine in a more targeted treatment setting.

It also places the company in direct competition for patients whose tumors develop ESR1 mutations after endocrine treatment.

The Competitive Landscape Is Getting More Crowded

ESR1-mutated ER-positive, HER2-negative metastatic breast cancer has become an active area of drug development.

The FDA has approved multiple newer therapies targeting estrogen signaling or related mechanisms in recent years, including camizestrant, vepdegestrant and imlunestrant in different treatment settings. (U.S. Food and Drug Administration)

On September 4, 2026, the FDA also granted accelerated approval to AstraZeneca's camizestrant in combination with a CDK4/6 inhibitor for adults with HR-positive, HER2-negative locally advanced or metastatic breast cancer when an ESR1 mutation is detected during treatment with an aromatase inhibitor and a CDK4/6 inhibitor. (U.S. Food and Drug Administration)

That means Lilly's new combination enters a rapidly developing treatment category with multiple targeted approaches.

Availability in the U.S.

Lilly said Inluriyo plus Verzenio is immediately available in the United States.

The availability of the combination also depends on identifying eligible patients through appropriate ESR1 testing.

This reinforces the role of molecular diagnostics in the commercial rollout of targeted cancer medicines.

What This Means for Oncology Care

The approval adds another oral treatment option for patients whose metastatic breast cancer has progressed after endocrine therapy and whose tumors carry specified ESR1 mutations.

For oncologists, the decision adds another combination to consider when selecting treatment for an increasingly molecularly defined patient population.

For patients, the significance is that tumor genetics can now play an even more direct role in determining treatment options.

For diagnostic companies, the approval further demonstrates the commercial importance of companion testing alongside targeted therapies.

Why This Matters

The approval is important because it combines a newer estrogen-receptor-targeting drug with an established CDK4/6 inhibitor and targets a group of patients whose disease can become resistant to endocrine therapy.

The FDA's data showed median progression-free survival of 11.1 months with the combination versus 5.5 months with Inluriyo alone in the 159-patient ESR1-mutated subgroup analyzed for the combination. (U.S. Food and Drug Administration)

It also illustrates the growing importance of identifying cancer biomarkers before selecting treatment.

Rather than treating metastatic ER-positive, HER2-negative breast cancer as a single disease category, drug development is increasingly focused on narrower groups defined by mutations and prior treatment history.

Looking Ahead

The key questions now will be how the combination performs in real-world treatment, how oncologists position it among competing therapies and how Lilly manages the growing ESR1-directed treatment market.

Longer-term survival data from EMBER-3 will also be important because the FDA said overall-survival data were still immature at the time of the interim analysis. (U.S. Food and Drug Administration)

The competitive landscape is also likely to remain active as other companies develop treatments aimed at ESR1-mutated breast cancer and related mechanisms of endocrine resistance.

The combination of targeted drugs and companion diagnostics is likely to remain a major feature of oncology commercialization.

What This Means for Healthcare Marketers

For healthcare marketers, this approval is a strong example of how drug demand and diagnostic demand can develop together.

The commercial opportunity is not limited to the therapy itself. ESR1 testing becomes part of the treatment pathway, creating potential demand across pharmaceutical, diagnostic and oncology-provider markets.

For B2B healthcare companies, signals such as FDA approvals, biomarker-specific indications, companion diagnostics and changes in treatment sequencing can reveal where new patient segments and provider needs are emerging.

In oncology, tracking the interaction between drug approvals and diagnostic requirements can therefore provide a clearer picture of market expansion than looking at drug approvals alone.

Key Takeaways

  • The FDA approved Eli Lilly's Inluriyo plus Verzenio for adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer after progression following at least one line of endocrine therapy. (U.S. Food and Drug Administration)
  • Inluriyo had already been FDA-approved as a standalone treatment for ESR1-mutated advanced or metastatic breast cancer in 2025. (U.S. Food and Drug Administration)
  • In the 159-patient ESR1-mutated subgroup analyzed for the combination, median progression-free survival was 11.1 months versus 5.5 months with Inluriyo alone. (U.S. Food and Drug Administration)
  • The progression-free-survival hazard ratio for the combination in that subgroup was 0.53. (U.S. Food and Drug Administration)
  • Objective response rates were 35% with the combination versus 15% with Inluriyo alone. (U.S. Food and Drug Administration)
  • Overall-survival data remained immature at the interim analysis. (U.S. Food and Drug Administration)
  • The FDA also approved Guardant360 CDx as a companion diagnostic for identifying relevant ESR1 mutations. (U.S. Food and Drug Administration)
  • Inluriyo is taken once daily, while Verzenio is taken twice daily. (U.S. Food and Drug Administration)
  • Lilly said the combination is available immediately in the U.S.